About Eligo Bioscience
Eligo Bioscience is a company based in Paris (France) founded in 2014 by David Bikard and Xavier Duportet.. Eligo Bioscience has raised $52.26 million across 7 funding rounds from investors including Khosla Ventures, Bpifrance and European Union. Eligo Bioscience offers products and services including GEM Platform. Eligo Bioscience operates in a competitive market with competitors including eGenesis, Beam Therapeutics, Korro Bio, Insmed and Scribe Therapeutics, among others.
- Headquarter Paris, France
- Founders David Bikard, Xavier Duportet
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eligo Bioscience
-
Annual Revenue
$1.92 M (USD)-16as on Dec 31, 2021
-
Net Profit
$-5.16 M (USD)-183as on Dec 31, 2021
-
EBITDA
$-7.47 M (USD)-120as on Dec 31, 2021
-
Total Equity Funding
$52.26 M (USD)
in 7 rounds
-
Latest Funding Round
$5 M (USD), Grant
May 13, 2025
-
Investors
Khosla Ventures
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eligo Bioscience
Eligo Bioscience offers a comprehensive portfolio of products and services, including GEM Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for in vivo editing of microbiome genes to influence health.
Funding Insights of Eligo Bioscience
Eligo Bioscience has successfully raised a total of $52.26M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $5 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Grant — $5.0M
-
First Round
First Round
(08 Jul 2015)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Grant - Eligo Bioscience | Valuation |
investors |
|
| Nov, 2023 | Amount | Series B - Eligo Bioscience | Valuation | Sanofi Ventures | |
| Mar, 2022 | Amount | Grant - Eligo Bioscience | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eligo Bioscience
Eligo Bioscience has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Khosla Ventures, Bpifrance and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location | |
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eligo Bioscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eligo Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eligo Bioscience Comparisons
Competitors of Eligo Bioscience
Eligo Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as eGenesis, Beam Therapeutics, Korro Bio, Insmed and Scribe Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
A CRISPR-based gene-editing platform is developed for therapeutic applications.
|
|
| domain | founded_year | HQ Location |
New genome engineering technology is provided for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eligo Bioscience
Frequently Asked Questions about Eligo Bioscience
When was Eligo Bioscience founded?
Eligo Bioscience was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Eligo Bioscience located?
Eligo Bioscience is headquartered in Paris, France.
Who is the current CEO of Eligo Bioscience?
Xavier Duportet is the current CEO of Eligo Bioscience. They have also founded this company.
Is Eligo Bioscience a funded company?
Eligo Bioscience is a funded company, having raised a total of $52.26M across 7 funding rounds to date. The company's 1st funding round was a Grant of $55.68K, raised on Jul 08, 2015.
What is the annual revenue of Eligo Bioscience?
Annual revenue of Eligo Bioscience is $1.92M as on Dec 31, 2021.
What does Eligo Bioscience do?
Eligo Bioscience was founded in 2014 in Paris, France, within the biotechnology sector. In vivo gene editing tools are provided to modify the microbiomes genetic composition. Diseases influenced by particular bacterial genes are targeted through this platform. Interactions between microbial communities and the host immune system are addressed in therapeutic applications. Operations focus on advancing microbiome-based interventions for health conditions.
Who are the top competitors of Eligo Bioscience?
Eligo Bioscience's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
What products or services does Eligo Bioscience offer?
Eligo Bioscience offers GEM Platform.
Who are Eligo Bioscience's investors?
Eligo Bioscience has 6 investors. Key investors include Khosla Ventures, Bpifrance, European Union, Sanofi Ventures, and Seventure Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.